ADM Diagnostics
ADMdx offers advanced brain image analysis for dementia diagnosis, aiding pharmaceutical trials and patient care.
Founded
2010ADMdx offers advanced brain image analysis for dementia diagnosis, aiding pharmaceutical trials and patient care.
ADM Diagnostics, founded with a mission to enhance the diagnosis and treatment of brain disorders, specializes in advanced brain image analysis. The company focuses on Alzheimer's disease and other forms of dementia, providing pharmaceutical companies with critical data to improve clinical trial outcomes. ADMdx offers comprehensive CNS imaging study services, including structural MRI, amyloid PET, tau PET, FDG PET, ASL, fMRI BOLD, and DTI. They are also developing diagnostic products for early and accurate disease detection.
Notable figures affiliated with ADMdx include its expert team of neuroscientists and imaging specialists. The company has achieved significant milestones, such as receiving 510(k) FDA clearance for its CorInsights® MRI product. This clearance underscores ADMdx's impact on the field by providing reliable tools for clinical trials and patient care. Their work supports pharmaceutical advancements and contributes to the broader understanding and treatment of neurodegenerative diseases.
Companies similar to ADM Diagnostics include Darmiyan, Diamir, Synaps Dx and NeuroVision Imaging.
ADM Diagnostics was founded in 2010.
ADM Diagnostics' headquarters is located in Northbrook, IL, US.
ADM Diagnostics' most recent funding round was for $2M (USD) in September 2022.
As of Sep 27, 2022, ADM Diagnostics has disclosed funding of $2.9M (USD). Undisclosed round amounts are excluded.
ADM Diagnostics has 30 employees as of Feb 5, 2024.
NeuroVision Imaging
neurovision.com
